You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
McKesson
Express Scripts
Dow

Last Updated: February 22, 2024

Ubrogepant - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for ubrogepant and what is the scope of patent protection?

Ubrogepant is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ubrogepant has one hundred and two patent family members in forty-five countries.

One supplier is listed for this compound.

Summary for ubrogepant
International Patents:102
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 34
Clinical Trials: 13
Patent Applications: 121
What excipients (inactive ingredients) are in ubrogepant?ubrogepant excipients list
DailyMed Link:ubrogepant at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ubrogepant
Generic Entry Date for ubrogepant*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ubrogepant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbViePhase 1
Chicago Headache Center & Research InstitutePhase 4
AbbViePhase 4

See all ubrogepant clinical trials

US Patents and Regulatory Information for ubrogepant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Abbvie UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ubrogepant

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2638042 2023C/541 Belgium ⤷  Try a Trial PRODUCT NAME: ATOGEPANT OF EEN FARMACEUTISCH AANVAARDAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1750 20230814
2638042 301248 Netherlands ⤷  Try a Trial PRODUCT NAME: ATOGEPANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1750 20230814
2638042 PA2023532 Lithuania ⤷  Try a Trial PRODUCT NAME: ATOGEPANTAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1750 20230811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
Johnson and Johnson
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.